Profitability Metrics

Gross Margin
94.45%
Operating Margin
35.13%
Net Margin
50.45%

Efficiency Metrics

Revenue per Expense Ratio
1.54
R&D as % of Revenue
19.62%

Earnings Quality

EBITDA Margin
43.41%
Income Tax Rate
9.98%
EPS
1.2200000000

Balance Sheet Analysis

Current Ratio
12.36
Cash Ratio
8.17
Working Capital
$17.54M
Debt to Equity
0.07
Debt to Assets
6.38%
Equity Ratio
87.91%

Cash Flow Analysis

Operating Cash Flow Ratio
41.72%
Free Cash Flow Ratio
41.67%
CapEx to Revenue
0.05%
Dividends Paid
$2.82M
Stock Buybacks
No buybacks
Total Shareholder Returns
$2.82M
Cash Position Change
452.76%

Key Takeaways (2023 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased dividend payments by 8.42%
  • Increased R&D investment by 21.56%

Detailed Growth Metrics

Core Performance

Revenue
5.87%
Net Income
450.71%
EPS
454.55%
Operating Income
188.49%

Operational Efficiency

R&D Expenses
21.56%
SG&A Expenses
-9.35%
Operating Cash Flow
720.21%
Free Cash Flow
10,846.00%

Balance Sheet Health

Assets
21.55%
Debt
-2.50%
Book Value per Share
20.46%
Inventory
26.41%

Shareholder Returns

Dividends per Share
8.42%
Shares Outstanding
0.54%

Long Term Trends

3Y Revenue/Share
-2.44%
5Y Revenue/Share
-13.27%
3Y Dividend/Share
0.00%
5Y Dividend/Share
0.00%